SecBot SecBot
PRESS-RELEASE ·Filed Jun 4, 2026

LYEL

Lyell Immunopharma, Inc
NEUTRAL
Impact 3/10
Horizonmonths Processed5mo ago WireGlobeNewswire
Press release · FDA
Actionable Insight • Neutral

Monitor EHA 2026 presentations for ronde-cel safety and translational insights. Focus on PiNACLE trial data in H2 2026 and the Phase 3 PiNACLE-H2H trial for future valuation drivers.

DirectionNeutral
Confidencehigh
Horizonmonths

How the stock moved after the report

NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$11.97
T+0 close · Jun 4, 2026 · via day close
Latest settled
+19.63%
T+60 · $14.32
Vs SPY
+15.63%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Jun 5 $11.97entry
  2. T+1 · 5mo ago +2.84%α +2.61% · $12.31
  3. T+5 · 5mo ago +12.78%α +12.21% · $13.50
  4. T+20 · 4mo ago +17.29%α +15.43% · $14.04
  5. T+60 · 3mo ago +19.63%α +15.63% · $14.32
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Lyell Immunopharma announced upcoming presentations of ronde-cel Phase 1/2 safety and translational data at the EHA 2026 Congress, but no clinical results were disclosed. The company's key catalysts remain the PiNACLE trial data expected in H2 2026 and a potential BLA submission in 2027. This is a routine pipeline update with no immediate impact.

Key Facts

  • Ronde-cel safety and translational data to be presented at EHA 2026 (June 11-14).
  • PiNACLE trial (3L+ LBCL) data expected H2 2026, pivotal data by mid-2027, BLA submission 2027.
  • No new clinical data or financial guidance provided in this release.

Financial Impact

No financial impact from this filing; key catalysts are future data readouts.

Risk Factors

  • Clinical data may not meet expectations; ronde-cel is still investigational.
  • Competition from approved CAR-T therapies (Yescarta, Breyanzi).

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
83% bullish (12 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3307088

Track record

21 reports on LYEL

Performance horizon

5 of 5 bullish or bearish reports moved the stock their way by T+1. Best: +17.99% at T+60 after the Jun 8, 2026 report. 5 of 5 went positive at some point.

Filters
  1. Nov 13, 20263d ago S-3 Neutral 3/10 Entry $14.30 Now $14.65 +2.45% settles Nov 17
  2. Nov 12, 20264d ago Insider Cluster Bullish 6/10 Entry $14.30 to $14.65 Now $14.65 +2.45% ▲ +2.45% +4.36% vs SPY
  3. Nov 10, 20266d ago SC 13G/A Neutral 2/10 Entry $16.86 to $15.64 Now $14.65 −13.11% ▼ −7.24% −6.88% vs SPY
  4. Nov 5, 202611d ago Insider Cluster Bullish 7/10 Entry $14.86 to $15.42 Now $14.65 −1.41% ▲ +3.77% +1.40% vs SPY
  5. Nov 4, 202612d ago 8-K Neutral 4/10 No price data
  6. Nov 4, 202612d ago Press Release Neutral 4/10 Entry $15.00 to $14.86 Now $14.65 −2.33% ▼ −0.93% −1.25% vs SPY
  7. Nov 4, 202612d ago 8-K Bearish 5/10 Entry $15.43 to $15.00 Now $14.65 +5.06% ▲ +2.79% −1.62% vs SPY
  8. Nov 4, 202612d ago Press Release Neutral 4/10 Entry $15.43 to $15.00 Now $14.65 −5.06% ▼ −2.79% +1.62% vs SPY
  9. Aug 25, 202611w ago Insider Cluster Neutral 4/10 Entry $14.80 to $14.61 Now $14.65 −1.01% ▼ −1.28% −1.94% vs SPY
  10. Jul 22, 202616w ago EFFECT Neutral 4/10 Entry $12.84 to $12.78 Now $14.65 +14.10% ▼ −0.47% +0.77% vs SPY
Showing 10 of 21

US Market Status

Market Closed · Opens in 6h 38m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Jun 4, 2026